Survival of @entity1 with XXXX in Germany and in the United States.

@entity1 @entity6595 @entity5 @entity1074 @entity1892
BACKGROUND AND AIM: This study aims to examine survival for @entity6595 and its main subtypes, @entity1074 ( @entity1074 ), and @entity1892 ( @entity1892 ), in Germany and in the United States. METHODS: Data for @entity1 diagnosed in 1997-2010 were used from 10 population-based German @entity5 registries and compared to the data from the US Surveillance, Epidemiology and End Results (SEER) 13 registries database. @entity1 age 15-74 diagnosed with @entity6595 were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival (RS) in 2002-2010 and survival trends from 2002-2004 to 2008-2010. RESULTS: Overall, the database included 1534 and 2688 @entity1 diagnosed with @entity6595 in 1997-2010 in Germany and in the United States, respectively. Survival was substantially higher for @entity1074 (5-year and 10-year RS: 89.0% and 80.9% in Germany, 93.8% and 86.8% in the United States) than for @entity1892 (67.5% and 59.2% in Germany, and 65.3% and 54.7% in the United States) in 2002-2010. Survival was slightly higher among female @entity1 and decreased by age for @entity6595 combined and its main subtypes. A slight, nonsignificant, increase in the 5-year RS for @entity6595 combined was observed in Germany and the United States, with increases in 5-year RS between 2002-2004 and 2008-2010 from 77.1% to 81.0% and from 77.3% to 82.0%, respectively. Five-year RS of @entity1074 exceeded 90% in 2008-2010 in both countries. CONCLUSIONS: Five-year RS of @entity1074 meanwhile exceeds 90% in both Germany and the United States, but @entity1892 has remained below 70% in both countries.
